康方生物(09926.HK)新型肿瘤免疫治疗新药之临床试验提前完成患者筛选入组

AAFN2020-12-02

康方生物公布，公司核心自主研发的、全球首创的新型肿瘤免疫治疗新药Cadonilimab (PD-1/CTLA-4双特异性抗体，研发代号：AK104)在中国用於经标准治疗後复发或转移性宫颈癌的注册性II期临床试验完成患者筛选入组。公司後续将根据主要终点分析结果与中国国家药品监督管理局药品审评中心进行新药上市申请前(Pre-NDA)沟通。如後续程序进展顺利，Cadonilimab将有望成为全球首款...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2088721980?lang=zh_CN&edition=full","thumbnail":"https://static.tigerbbs.com/df4ec61541b268a5353585001973d7cb","is_english":false,"pubTime":"2020-12-02 09:42","share_image_url":"https://static.laohu8.com/51f6b9126f36f92bbf92982596066e5a","id":"2088721980","market":"us","top_or_hot":-1,"title":"康方生物(09926.HK)新型肿瘤免疫治疗新药之临床试验提前完成患者筛选入组","media":"AAFN","content":"<div>\n<p>康方生物  公布，公司核心自主研发的、全球首创的新型肿瘤免疫治疗新药Cadonilimab (PD-1/CTLA-4双特异性抗体，研发代号：AK104)在中国用於经标准治疗後复发或转移性宫颈癌的注册性II期临床试验完成患者筛选入组。公司後续将根据主要终点分析结果与中国国家药品监督管理局药品审评中心进行新药上市申请前(Pre-NDA)沟通。如後续程序进展顺利，Cadonilimab将有望成为全球首款...</p>\n\n<a href=\"http://www.aastocks.com/apps/data/iphone/news/newscontent.aspx?newsid=NOW.1060434&style=5&chgstyle=1&categoryid=stock&width=320&market_id=hk&fontary=3&platform=iPhone&language=sc&isfirstreq=1&sourceid=aafn&datatype=0\">网页链接</a>\n\n</div>\n","source":"aastocks","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>康方生物(09926.HK)新型肿瘤免疫治疗新药之临床试验提前完成患者筛选入组</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n康方生物(09926.HK)新型肿瘤免疫治疗新药之临床试验提前完成患者筛选入组\n</h2>\n\n<h4 class=\"meta\">\n\n\n2020-12-02 09:42 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.aastocks.com/apps/data/iphone/news/newscontent.aspx?newsid=NOW.1060434&style=5&chgstyle=1&categoryid=stock&width=320&market_id=hk&fontary=3&platform=iPhone&language=sc&isfirstreq=1&sourceid=aafn&datatype=0><strong>AAFN</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>康方生物  公布，公司核心自主研发的、全球首创的新型肿瘤免疫治疗新药Cadonilimab (PD-1/CTLA-4双特异性抗体，研发代号：AK104)在中国用於经标准治疗後复发或转移性宫颈癌的注册性II期临床试验完成患者筛选入组。公司後续将根据主要终点分析结果与中国国家药品监督管理局药品审评中心进行新药上市申请前(Pre-NDA)沟通。如後续程序进展顺利，Cadonilimab将有望成为全球首款...</p>\n\n<a href=\"http://www.aastocks.com/apps/data/iphone/news/newscontent.aspx?newsid=NOW.1060434&style=5&chgstyle=1&categoryid=stock&width=320&market_id=hk&fontary=3&platform=iPhone&language=sc&isfirstreq=1&sourceid=aafn&datatype=0\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09926","symbol_name":"康方生物","start_time":0,"source_url":"http://www.aastocks.com/apps/data/iphone/news/newscontent.aspx?newsid=NOW.1060434&style=5&chgstyle=1&categoryid=stock&width=320&market_id=hk&fontary=3&platform=iPhone&language=sc&isfirstreq=1&sourceid=aafn&datatype=0","article_id":"2088721980","we_media_id":null,"thumbnails":["https://static.tigerbbs.com/df4ec61541b268a5353585001973d7cb"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2088721980","pubTimestamp":1606873351,"columns":[],"sourceInfo":{"source_id":"aastocks","name":"阿思达克财经"},"weMediaInfo":null,"summary":"康方生物  公布，公司核心自主研发的、全球首创的新型肿瘤免疫治疗新药Cadonilimab (PD-1/CTLA-4双特异性抗体，研发代号：AK104)在中国用於经标准治疗後复发或转移性宫颈癌的注册性II期临床试验完成患者筛选入组。公司後续将根据主要终点分析结果与中国国家药品监督管理局药品审评中心进行新药上市申请前(Pre-NDA)沟通。如後续程序进展顺利，Cadonilimab将有望成为全球首款获批上市的基於PD-1的双特异性抗体新药。(sw/k)~阿思达克财经新闻网址: www.aastocks.com","collect":0,"end_time":0,"defaultTopTitle":"aastocks.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"09926":"康方生物","03347":"泰格医药"},"translate_title":"The clinical trial of Kangfang Biology (09926. HK) New Tumor Immunotherapy Drug Completed ahead of schedule and the patients were screened into the group.","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"90010":1,"09926":1,"03347":1},"content_text":"康方生物  公布，公司核心自主研发的、全球首创的新型肿瘤免疫治疗新药Cadonilimab (PD-1/CTLA-4双特异性抗体，研发代号：AK104)在中国用於经标准治疗後复发或转移性宫颈癌的注册性II期临床试验完成患者筛选入组。公司後续将根据主要终点分析结果与中国国家药品监督管理局药品审评中心进行新药上市申请前(Pre-NDA)沟通。如後续程序进展顺利，Cadonilimab将有望成为全球首款获批上市的基於PD-1的双特异性抗体新药。(sw/k)~阿思达克财经新闻网址: www.aastocks.com","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2088721980","isCrawlerRequest":true}